Shots:
- Anivive has reported completion of its pivotal trial of Laverdia-CA1 to treat dogs with lymphoma where, the final study site was closed on Dec 12, 2024
- The trial assessed Laverdia-CA1 vs PBO in dogs (n=150; selected via AniviveTrial platform from >700 applications) in 12 US sites with results expected in coming months
- Additionally, Anivive plans to submit the effectiveness technical section for the US FDA review this summer, with all other major NADA sections approved, & will seek complete approval in Brazil, Australia, UK, & EU post data finalization
Ref: Prnewswire | Image: Anivive
Related News:- Anivive Lifesciences Receives $20M Funding from Leonid Capital Partners to Develop Novel Programs for Pets
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
